Company Overview - Viking Therapeutics is a San Diego-based company focused on metabolic and endocrine disorders with approximately 55 employees [3]. Clinical Programs - The company is developing VK2735, a GLP-1/GIP dual agonist for obesity, which is currently in a Phase III program known as the VANQUISH program [3]. - An oral formulation of VK2735 has recently completed a Phase II study, with data to be discussed in the presentation [3]. - An amylin agonist is approaching the clinic, with an IND filing expected in the first quarter [4]. - Additional programs include VK2809, which has completed a Phase IIb study in MASH, and VK0214, which has gone through a Phase Ib study in X-linked adrenoleukodystrophy; however, these programs are not actively being developed [4].

Viking Therapeutics Conference Call Summary Company Overview - **Company**: Viking Therapeutics (NasdaqCM: VKTX) - **Focus**: Metabolic and endocrine disorders - **Location**: San Diego, California - **Employees**: Approximately 55 Key Programs and Developments - **VK2735**: A GLP-1 GIP dual agonist for obesity - Currently in Phase III program called the VANQUISH program [4][35] - Oral formulation recently completed Phase II study [4][35] - **Amylin Agonist**: Expected to file an IND in the first quarter of 2026 [5][36] - **VK2809**: A thyroid receptor beta agonist that has completed a Phase IIb study in NASH [5] - **VK0214**: Another thyroid receptor beta agonist that has completed a Phase Ib study in X-linked adrenoleukodystrophy [5] Clinical Data and Efficacy - **VK2735 Oral Formulation**: - Phase II study showed up to 12.2% body weight reduction after 13 weeks of dosing [20][29] - Weight loss maintained for four weeks after the last dose [10][20] - Excellent tolerability with most adverse events classified as mild to moderate [21][29] - **VK2735 SubQ Formulation**: - Phase II study showed weight loss of 9% to 15% from baseline after 13 weeks [25][30] - Durable weight loss observed 21 days after the last dose [23][30] - Excellent tolerability with 98% of adverse events classified as mild to moderate [24][30] Pipeline and Future Studies - **VANQUISH Phase III Studies**: - VANQUISH I: Completed enrollment, focusing on obesity [30][35] - VANQUISH II: Expected to complete enrollment in the first quarter of next year [30][35] - **Maintenance Study**: Ongoing with a focus on transitioning from weekly to monthly dosing [33][34] Financial Overview - **Cash Position**: Over $700 million as of the third quarter, expected to fund through the VANQUISH Phase III data readouts [34][35] Additional Insights - The company is prioritizing mid-range doses for the oral formulation based on pharmacokinetics and gastrointestinal tolerability [37] - The potential for transitioning from SubQ to oral dosing to maintain weight loss is being explored [37] This summary encapsulates the key points from the Viking Therapeutics conference call, highlighting the company's focus on metabolic disorders, clinical program advancements, and financial health.